Dissection of PIM serine/threonine kinases in FLT3-ITD-induced leukemogenesis reveals PIM1 as regulator of CXCL12-CXCR4-mediated homing and migration.
FLT3-ITD-mediated leukemogenesis is associated with increased expression of oncogenic PIM serine/threonine kinases. To dissect their role in FLT3-ITD-mediated transformation, we performed bone marrow reconstitution assays. Unexpectedly, FLT3-ITD cells deficient for PIM1 failed to reconstitute lethally irradiated recipients, whereas lack of PIM2 induction did not interfere with FLT3-ITD-induced disease. PIM1-deficient bone marrow showed defects in homing and migration and displayed decreased surface CXCR4 expression and impaired CXCL12-CXCR4 signaling. Through small interfering RNA-mediated knockdown, chemical inhibition, expression of a dominant-negative mutant, and/or reexpression in knockout cells, we found PIM1 activity to be essential for proper CXCR4 surface expression and migration of cells toward a CXCL12 gradient. Purified PIM1 led to the phosphorylation of serine 339 in the CXCR4 intracellular domain in vitro, a site known to be essential for normal receptor recycling. In primary leukemic blasts, high levels of surface CXCR4 were associated with increased PIM1 expression, and this could be significantly reduced by a small molecule PIM inhibitor in some patients. Our data suggest that PIM1 activity is important for homing and migration of hematopoietic cells through modification of CXCR4. Because CXCR4 also regulates homing and maintenance of cancer stem cells, PIM1 inhibitors may exert their antitumor effects in part by interfering with interactions with the microenvironment.
Grundler
Rebekka
R
Department of Internal Medicine III, Technical University, Munich 81739, Germany.
Brault
Laurent
L
Gasser
Christelle
C
Bullock
Alex N
AN
Dechow
Tobias
T
Woetzel
Sabine
S
Pogacic
Vanda
V
Villa
Antonello
A
Ehret
Sabine
S
Berridge
Georgina
G
Spoo
Anke
A
Dierks
Christine
C
Biondi
Andrea
A
Knapp
Stefan
S
Duyster
Justus
J
Schwaller
Juerg
J
D000818:Animals; D001854:Bone Marrow Cells / Q000166:cytology* / Q000378:metabolism; D002465:Cell Movement / Q000502:physiology*; D002471:Cell Transformation, Neoplastic / Q000378:metabolism*; D054377:Chemokine CXCL12 / Q000378:metabolism; D017931:DNA Primers / Q000235:genetics; D005434:Flow Cytometry; D006801:Humans; D015151:Immunoblotting; D016130:Immunophenotyping; D019169:Jurkat Cells; D015470:Leukemia, Myeloid, Acute / Q000378:metabolism*; D051379:Mice; D018345:Mice, Knockout; D010766:Phosphorylation; D051573:Proto-Oncogene Proteins c-pim-1 / Q000235:genetics / Q000378:metabolism*; D034622:RNA Interference; D019718:Receptors, CXCR4 / Q000378:metabolism; D020133:Reverse Transcriptase Polymerase Chain Reaction; D019032:Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization; D051941:fms-Like Tyrosine Kinase 3
C514936:CXCR4 protein, mouse; D054377:Chemokine CXCL12; C515256:Cxcl12 protein, mouse; D017931:DNA Primers; D019718:Receptors, CXCR4; C497971:Flt3 protein, mouse; D051941:fms-Like Tyrosine Kinase 3; D051573:Proto-Oncogene Proteins c-pim-1
Mol Cancer Ther. 2006 Dec;5(12):3113-21
17172414
Blood. 2005 Sep 15;106(6):1901-10
15890683
Leukemia. 2006 Nov;20(11):1915-24
16900209
Cancer Res. 2007 Jul 15;67(14):6916-24
17638903
Immunol Rev. 1999 Apr;168:33-49
10399063
Mol Cell Biol. 2004 Jul;24(13):6104-15
15199164
J Biol Chem. 1999 Oct 22;274(43):31076-86
10521508
FEBS Lett. 2004 Jul 30;571(1-3):43-9
15280015
Blood. 2005 Feb 15;105(4):1759-67
15498859
Blood. 2005 Jun 15;105(12):4792-9
15718420
Nat Genet. 2002 Sep;32(1):153-9
12185366
Haematologica. 2005 Jul;90(7):949-68
15996933
Blood. 2007 Jan 15;109(2):786-91
16888090
Nat Genet. 2003 May;34(1):70-4
12692554
J Cell Mol Med. 2008 Apr;12(2):374-90
18182063
Biochim Biophys Acta. 2007 Apr;1768(4):952-63
17169327
Nature. 2005 Jun 16;435(7044):969-73
15959517
Blood. 2003 Jun 1;101(11):4245-52
12609846
J Biol Chem. 2005 Jul 1;280(26):24698-705
15849194
Proc Natl Acad Sci U S A. 1989 Nov;86(22):8857-61
2682662
Blood. 2006 Mar 1;107(5):1761-7
16269611
Eur J Immunol. 2003 May;33(5):1328-33
12731058
Leukemia. 2007 Jun;21(6):1249-57
17410186
Curr Mol Med. 2005 Nov;5(7):615-23
16305488
Biochem Biophys Res Commun. 2006 Jan 27;339(4):1138-47
16343435
Mol Cancer Res. 2007 Sep;5(9):909-22
17855660
Science. 1999 Feb 5;283(5403):845-8
9933168
Cancer Res. 2005 Dec 15;65(24):11392-9
16357147
J Cell Sci. 2007 Jan 15;120(Pt 2):219-28
17179206
Br J Haematol. 2006 Sep;134(5):500-9
16869825
Leukemia. 2008 Jan;22(1):78-86
17943165
Blood. 2002 Feb 15;99(4):1117-29
11830456
Blood. 2004 Jul 15;104(2):550-7
15054042
J Med Chem. 2005 Dec 1;48(24):7604-14
16302800
Blood. 1993 Sep 1;82(5):1445-52
7689870
Leukemia. 2003 May;17(5):829-38
12750693
J Biol Chem. 2005 Dec 16;280(50):41675-82
16227208
Blood. 2005 Jun 1;105(11):4477-83
15705789
Blood. 2003 Apr 15;101(8):3164-73
12468433
EMBO J. 1996 May 15;15(10):2425-33
8665850
Histol Histopathol. 2004 Jan;19(1):299-309
14702198
J Immunol. 1996 Jan 15;156(2):549-57
8543805
Cancer Res. 2006 Apr 1;66(7):3828-35
16585210
Cancer Res. 2004 Apr 15;64(8):2817-24
15087398
Mol Cell. 2000 Sep;6(3):693-704
11030348